Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
نویسندگان
چکیده
Following publication of the original article [1] the authors reported that the first affiliation ("Medical Center of the Graduate School, Nanchang University, China") had been added in error, and that the correct author information is as given in this erratum.
منابع مشابه
Safety of sodium-glucose co-transporter 2 inhibitors during Ramadan fasting: Evidence, perceptions and guidelines
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new glucose-lowering therapy for T2DM with documented benefits on blood glucose, hypertension, weight reduction and long term cardiovascular benefit. They have an inherent osmotic diuretic effect and lead to some volume loss and possible dehydration. There is some concern about the safety of using SGLT2 inhibitors in Muslim type 2 diabete...
متن کاملSGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Diabetic kidney disease (DKD) is the most common cause of end stage renal disease. The comprehensive management of DKD depends on combined target-therapies for hyperglycemia, hypertension, albuminuria, and hyperlipaemia, etc. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, the most recently developed oral hypoglycemic agents acted on renal proximal tubules, suppress glucose reabsorption and...
متن کاملPreventing diabetic renal disease: the potential reno-protective effects of SGLT2 inhibitors
Diabetic renal disease is associated with increased cardiovascular risk and is one of the leading causes of end-stage renal disease worldwide. A combination of hyperglycaemia and hypertension drives the development and progression of diabetic renal disease, with glomerular hyperfiltration being an early manifestation of the disease process. Sodiumglucose linked transporter 2 (SGLT2) inhibitors ...
متن کاملPractical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for the treatment of type 2 diabetes. They block the reabsorption of filtered glucose in kidneys, mainly in proximal renal tubules, resulting in increased urinary glucose excretion and correction of the diabetes-related hyperglycemia. Beyond improving glucose control, SGLT2 inhibitors offer potential b...
متن کامل